Rauchhaus M, Koloczek V, Volk H, Kemp M, Niebauer J, Francis D P, Coats A J, Anker S D
Department of Clinical Cardiology, Imperial College School of Medicine at the National Heart and Lung Institute, London, UK.
Int J Cardiol. 2000 Nov-Dec;76(2-3):125-33. doi: 10.1016/s0167-5273(00)00224-2.
We studied the clinical and immunological importance of fasting cholesterol, HDL, LDL and triglycerides in patients with chronic heart failure in relation to plasma concentrations of tumor necrosis factor-alpha (TNFalpha), soluble TNF receptor-1 and -2 (sTNF-R1 and -R2), and a ratio potentially indicating recent endotoxin bioactivity (soluble [s] CD14/total cholesterol).
Fifty-eight stable, non-oedematous patients with established heart failure and 19 controls were studied prospectively. Concentrations of sTNF-R1 and sCD14 were higher in patients than in controls (1238+/-96 vs. 632+/-72 pg/ml, P=0.005 and 3401+/-120 vs. 2775+/-139 pg/ml, P=0.007, respectively), whereas those of TNFalpha (9.3+/-1.1 vs. 6.7+/-0.6 pg/ml) and sTNF-R2 (2464+/-145 vs. 1920+/-303 pg/ml) were not. Cholesterol (5.6+/-0.1 vs. 5.5+/-0.2 mmol/l) and LDL (3.5+/-0.1 vs. 3.6+/-0.2 mmol/l) were not different (both P>0.75). Patients had lower HDL (1.10+/-0.04 vs. 1.4+/-0.06 mmol/l, P=0.0004) and higher triglycerides (2.1+/-0.1 vs. 1.1+/-0.1 mmol/l, P=0.0006). Aetiology and the presence of cardiac cachexia did not influence the lipid profile. Correlations in patients: cholesterol vs. TNFalpha (r=-0.40, P=0.003), vs. sTNF-R1 (r=-0.24, P=0.08), vs. sTNF-R2 (r=-0.29, P<0.04); sCD14 vs. TNFalpha (r=0.44, P=0.005), vs. sTNF-R1: (r=0.65, P<0.0001), vs. sTNF-R2 (r=0.59, P<0. 0001). The sCD14/cholesterol ratio related powerfully to TNFalpha (r=0.60), sTNF-R1 (r=0.74), and sTNF-R2 (r=0.65, all P<0.0001). This sCD14/cholesterol ratio emerged as the strongest predictor of TNFalpha, sTNF-R1 and -R2 (all P<0.01), independently of renal and hepatic function, and conventional measures of disease severity. A cholesterol level <5.2 mmol/l (n=18) significantly predicted a poor clinical outcome (P<0.04, RR 3.5, 95% CI 1.1-11.0) independently of peak VO(2) (P=0.07), NYHA class (P=0.08), aetiology (P=0.14), and age, body wasting, sodium, LVEF, heart rate, and blood pressure (all P>0.20, follow-up 12 months, event rate 26%).
Our data supports previous findings that lower, rather than higher cholesterol levels are associated with poor clinical outcome in patients with chronic heart failure. This relationship is unrelated to heart failure aetiology, and suggests that the classic risk profile is not longer relevant in established heart failure. The little-recognised ability of all lipoprotein fractions to bind endotoxin and to serve as natural buffer substances may explain this relationship between lower lipoprotein levels, higher cytokine concentrations and impaired prognosis.
我们研究了慢性心力衰竭患者空腹胆固醇、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)和甘油三酯的临床及免疫学意义,及其与肿瘤坏死因子-α(TNFα)、可溶性TNF受体-1和-2(sTNF-R1和sTNF-R2)血浆浓度,以及一个可能指示近期内毒素生物活性的比值(可溶性[s]CD14/总胆固醇)之间的关系。
前瞻性研究了58例病情稳定、无水肿的确诊心力衰竭患者和19例对照者。患者的sTNF-R1和sCD14浓度高于对照者(分别为1238±96 vs. 632±72 pg/ml,P = 0.005;3401±120 vs. 2775±139 pg/ml,P = 0.007),而TNFα(9.3±1.1 vs. 6.7±0.6 pg/ml)和sTNF-R2(2464±145 vs. 1920±303 pg/ml)浓度则无差异。胆固醇(5.6±0.1 vs. 5.5±0.2 mmol/l)和LDL(3.5±0.1 vs. 3.6±0.2 mmol/l)无差异(P均>0.75)。患者的HDL较低(1.10±0.04 vs. 1.4±0.06 mmol/l,P = 0.0004),甘油三酯较高(2.1±0.1 vs. 1.1±0.1 mmol/l,P = 0.0006)。病因及心脏恶病质的存在不影响血脂谱。患者中的相关性:胆固醇与TNFα(r = -0.40,P = 0.003)、与sTNF-R1(r = -0.24,P = 0.08)、与sTNF-R2(r = -0.29,P<0.04);sCD14与TNFα(r = 0.44,P = 0.005)、与sTNF-R1(r = 0.65,P<0.0001)、与sTNF-R2(r = 0.59,P<0.0001)。sCD14/胆固醇比值与TNFα(r = 0.60)、sTNF-R1(r = 0.74)和sTNF-R2(r = 0.65,P均<0.0001)密切相关。该sCD14/胆固醇比值是TNFα、sTNF-R1和sTNF-R2的最强预测指标(P均<0.01),独立于肾功能和肝功能以及疾病严重程度的传统指标。胆固醇水平<5.2 mmol/l(n = 18)显著预测不良临床结局(P<0.04,相对危险度3.5,95%可信区间1.1 - 11.0),独立于峰值摄氧量(P = 0.07)、纽约心脏协会(NYHA)心功能分级(P = 0.08)、病因(P = 0.14)以及年龄、身体消瘦、钠、左心室射血分数(LVEF)、心率和血压(P均>0.20,随访12个月,事件发生率26%)。
我们的数据支持先前的研究结果,即慢性心力衰竭患者胆固醇水平较低而非较高与不良临床结局相关。这种关系与心力衰竭病因无关,提示经典的风险谱在确诊心力衰竭中不再相关。所有脂蛋白组分结合内毒素并作为天然缓冲物质的鲜为人知的能力,可能解释了较低脂蛋白水平、较高细胞因子浓度与预后受损之间的这种关系。